GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | BCL2 | affects expression | EXP | | 6480464 | CTD | Methotrexate affects the expression of BCL2 mRNA | PMID:23792648 PMID:25330300 | BCL2 | decreases expression | EXP | | 6480464 | CTD | Methotrexate results in decreased expression of BCL2 mRNA; Methotrexate results in decreased expression of BCL2 protein | PMID:17132110 PMID:23799623 PMID:34350509 | BCL2 | increases expression | EXP | | 6480464 | CTD | Methotrexate results in increased expression of BCL2 mRNA | PMID:29027214 | BCL2 | multiple interactions | EXP | | 6480464 | CTD | [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; [Methotrexate co-treated with theaflavin-3,3'-digallate] results in decreased expression of BCL2 protein; Aspirin inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; SOD2 protein polymorphism affects the reaction [Methotrexate affects the expression of BCL2 mRNA] | PMID:21182165 PMID:23799623 PMID:25330300 PMID:34350509 | BCL2 | decreases expression | ISO | Bcl2 (Rattus norvegicus) | 6480464 | CTD | Methotrexate results in decreased expression of BCL2 mRNA; Methotrexate results in decreased expression of BCL2 protein | PMID:18803016 PMID:28414158 PMID:28479099 PMID:31362085 PMID:33720507 PMID:37312617 | BCL2 | increases expression | ISO | Bcl2 (Rattus norvegicus) | 6480464 | CTD | Methotrexate results in increased expression of BCL2 mRNA | PMID:29027214 | BCL2 | multiple interactions | ISO | Bcl2 (Rattus norvegicus) | 6480464 | CTD | 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; [Aspartame co-treated with Methotrexate] results in decreased expression of BCL2 mRNA; [Aspartame co-treated with Methotrexate] results in decreased expression of BCL2 protein; Carnitine inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; Liraglutide inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; Methotrexate inhibits the reaction [Freund's Adjuvant results in decreased expression of BCL2 protein]; sinapinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]; TGFA protein inhibits the reaction [Methotrexate results in decreased expression of BCL2 mRNA]; TGFA protein inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein] | PMID:18803016 PMID:25009784 PMID:28414158 PMID:28479099 PMID:30025850 PMID:31362085 PMID:33720507 PMID:37312617 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |